Investing.com8 日
決算発表：Dr. Reddy'sが力強い成長と戦略的拡大を報告
同社はGLP-1 APIの完全な一貫生産能力を有している。 Dr. Reddy's Laboratoriesは引き続き強力な業績と将来の成長に向けた明確な戦略を示しています。戦略的買収、製品ミックスの改善、新市場への拡大に焦点を当てることで、同社は継続的な成功に向けて良好な ...
MSN による配信10 日
NIFTY 50: 5:1 STOCK SPLIT done! Should you BUY top pharma company's after Q2 results?
The pharma major announced its Q2 earnings for the financial year 2024-25 on Tuesday. Shares of Dr Reddy's Laboratories ...
Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%
Dr Reddy's Lab’s average revenue will potentially increase 12 per cent Y-o-Y to Rs 7,734 crore as against Rs 6,902 crore in ...
cnbctv1810 日
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.